NKY(SZ:300109) Sou Hu Cai Jing·2025-08-26 12:45Financial Performance - The company's operating revenue for the current reporting period is approximately 644 million yuan, a decrease from 734 million yuan in the same period last year, representing a decline of about 12.3% [1] - The net profit attributable to shareholders is approximately 139 million yuan, down from 213 million yuan year-on-year, indicating a decrease of about 34.2% [1] - The net profit after deducting non-recurring gains and losses is approximately 129 million yuan, compared to 218 million yuan in the previous year, reflecting a decline of about 40.7% [1] - The net cash flow from operating activities is approximately 74 million yuan, down 52.97% from 158 million yuan in the same period last year [24] - Basic earnings per share are 0.29 yuan, down from 0.45 yuan year-on-year [1] Asset and Liability Changes - As of the end of the current reporting period, total assets amount to approximately 4.695 billion yuan, an increase from 4.372 billion yuan at the end of the previous year [1] - The net assets attributable to shareholders are approximately 3.779 billion yuan, up from 3.638 billion yuan at the end of the previous year [1] - Long-term borrowings have increased by 674.28%, contributing to a rise in total assets ratio by 2.93 percentage points [38] - The company's inventory value is 400 million yuan, accounting for 10.59% of net assets, with an increase of approximately 22.79 million yuan [41] Profitability Metrics - The weighted average return on equity for the first half of 2025 is 3.75%, a decrease of 2.16 percentage points compared to the previous year [23] - The company's gross profit margin has shown fluctuations, with the latest data indicating a decline compared to industry averages [19] Business Segments - The company operates in two main sectors: fine chemicals and precision medicine, with a focus on producing and selling PVP series products and developing a medical service platform [9] - The revenue composition for the first half of 2025 includes various product lines, with significant contributions from PVP products and precision medical services [15] Market Valuation - As of August 26, the company's price-to-earnings ratio (TTM) is approximately 33.37, the price-to-book ratio (LF) is about 2.44, and the price-to-sales ratio (TTM) is around 6.07 [1]